Synthio Labs
Category: Voice / Speech AI
Synthio Labs is a clinical-grade voice AI company building AI agents for life sciences customer engagement, focusing on automating compliance-driven interactions and enhancing patient engagement. Synthio Labs was founded in 2024. The company is led by Supreet Deshpande. Based in San Francisco, United States. Team size: 11-50. Total funding raised: $5.5 million. Latest round: Seed. Key investors include Elevation Capital, 1984 Ventures, Peak XV Partners, Y Combinator, Pioneer Fund.
- Founded
- 2024
- Headquarters
- San Francisco, United States
- Team size
- 11-50
- Total funding
- $5.5 million
Value proposition
Delivers clinical-grade AI interactions for compliance conversations, rapid patient outreach (e.g., 5,000+ eczema patients reached in 48 hours), and scalable omnichannel engagement tailored for clinical and regulatory requirements
Products and solutions
Jarvis: Voice AI copilot for field teams, Ather: Voice AI Agents for HCP Engagement, Helix: Voice AI Agents for Patient Support, Simulation Studio: AI digital twins for market research, Polaris HQ: Talk to your data / enterprise multi-agent data intelligence
Unique value
First AI Medical Expert for Pharma GTM teams, integrating Voice AI with clinical compliance and patient engagement
Target customer
Pharmaceutical companies, healthcare providers, and life sciences organizations requiring AI-driven engagement with clinicians and patients
Industries served
Pharmaceuticals, Life Sciences, Healthcare
Technology advantage
Proprietary AI Operating System unifying three platforms; leverages generative AI for life sciences GTM (CEO's prior McKinsey expertise)
How they differentiate
Synthio Labs specializes in clinical-grade voice AI tailored for life sciences engagement, offering conversational platforms specifically designed for interactions between life sciences organizations, clinicians, and patients. Competitors are more general B2B tools.
Main competitors
Voice AI platforms for healthcare, Traditional pharma engagement tools, General B2B voice AI solutions
Key partnerships
Y Combinator (Spring 2025 batch), Elevation Capital (lead seed investor), 1984 Ventures, Peak XV Partners, Pioneer Fund, Enterprise life sciences deployments US/Europe; ASCO 2026 Ather demo
Notable customers
Soteri Skin, Jazz Pharmaceuticals, Novartis, Sobi, Grace Therapeutics, Reachhealth, Precision AQ, Unnamed Top 3/Top 5 pharma
Major milestones
Y Combinator Spring 2025 batch, Raised $5.5M total seed ($500K YC Jun 2025 + $5M Nov 2025 led by Elevation Capital), Launched AI medical expert platform (2025), Named on Forbes most promising YC Spring startups list (2025), Scaled to 29 employees (as of mid-2026), ASCO 2026 live Ather multimodal agent demos with oncologists, Named enterprise customers including Jazz, Novartis, Sobi, Soteri Skin
Growth metrics
5,000+ patient conversations in 48 hours (Soteri Skin eczema engagement); homepage metrics: 10K+ patients engaged, 500K+ minutes of voice AI, 10B+ LLM tokens for pharma, 99% CSAT; field deployment: 90% weekly active usage / ~10 hrs/week saved per rep (Immunology team case)
Market positioning
Positioned as a niche AI solution for the life sciences industry, focusing on stakeholder engagement through voice AI technology
Geographic focus
Primarily U.S.-based with global reach in the life sciences sector
Patents and IP
No public patents listed in recent searches; focus on trade secrets and IP around AI workflow integration in regulated healthcare environments
About Supreet Deshpande
Over a decade at the intersection of AI/ML and life sciences, delivering AI solutions across the pharmaceutical value chain. Previously led 'Gen AI for Life Sciences' initiatives at McKinsey & Company, and worked at JPMorgan Chase & Co., ZS, and Winkl A Good Creator Co.
More Voice / Speech AI companies
Official website: https://synthiolabs.com